Information  X 
Enter a valid email address

Societe Generale SA (IRSH)

  Print   

Thursday 29 July, 2021

Societe Generale SA

Form 8.3 - UDG Healthcare plc

RNS Number : 8960G
Societe Generale SA
29 July 2021
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

Société Générale S.A.

Companydealtin

UDG Healthcare plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

€0.05 ordinary shares

Date of dealing

28/07/2021

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

17,840,898

7.08

12,662

0.01

(2) Derivatives (other than options)

0

0.00

12,043,405

4.78

(3) Options and agreements to purchase/sell

0

0.00

0

0.00

Total

17,840,898

7.08

12,056,067

4.78

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit GBP (Note 5)

Purchase

1,000

10.79

Purchase

1

10.79

Purchase

232

10.79

Purchase

9

10.79

Purchase

2,222

10.79

Sale

3,466

10.78

Sale

3,013

10.78

Total Purchases

3,464

 

Total Sales

6,479

 

 

Derivatives transactions (other than options transactions)

 

Product name,
e.g. CFD

Nature of transaction
(Note 6)

Number of relevant securities
(Note 7)

Price per unit GBP
(Note 5)

 

 

 

 

 

(b)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

(c)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.  OTHER INFORMATION

Agreements, arrangements, or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or   disposal   of   any  relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)     No

 

Dateofdisclosure

29/07/2021

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

 

If aconnectedEFM,statenatureofconnection (Note 10)

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEEAXXNALKFEEA

a d v e r t i s e m e n t